 |
|
|
| |
Modeling suggests that undetectable HCV at week 2 of DAA
therapy could identify patients for shorter treatment duration
|
| |
| |
EASL 2024 June 5-8
Written by Jules Levin
Ashish Goyal1, Ohad Etzion2, Kimberly Page3, Tatyana Kushner4, Yedidya Saiman5, Scott Cotler1, Harel Dahari1.
|
| |
|
|
|
|
|
